Grant: Operating Grant-PA: INMD Start Up Funds (bridge funding) - Clinician Scientists
Université Laval
$100,000.00
Development and Validation of a Non-invasive assay to Diagnose Rejection in Renal Transplant Recipients
EF 2013-14
Résumé
In the last two decades, thanks to the development of new immunosuppressive medication, the rejection rate of transplanted kidneys in the first year following transplant have decreased substantially. Unfortunately, this success has not translated into a significant increase in the long-term graft survival. This is now the most challenging task in transplantation: to prevent premature graft loss. We know that rejection is the main mechanism leading to premature graft failure. The problem lies in the fact that it is often diagnosed late, because we need to perform a biopsy to confirm the diagnosis. This is a complex and sometimes risky procedure, such that it cannot be used repeatedly to monitor the transplanted kidney. There is no doubt that a simple test, for instance based on a peripheral blood puncture or urine sample, would be an ideal tool.
Our main objective is to develop such a test and to make it applicable in the clinical setting. Our preliminary studies have shown that in kidney recipients with rejection, two different markers, IL-6 measured in the blood, and CXCL10 measured in the urine, can distinguish rejectors from non rejectors. These samples were procured by a simple routine test and are therefore simple techniques that seems promising to identify patients in rejection. We now want to know if, by measuring these markers, we can predict which patients will develop a rejection episode, before irreversible damage occurs within the graft.
Our hope is that this new knowledge will help us to diagnose rejection earlier and hence maximize treatment, in order to improve the life expectancy of the transplanted kidneys and their recipients.
Programme
Operating Grant-PA: INMD Start Up Funds (bridge funding) - Clinician Scientists
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
298522
Name
De Serres Sacha
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Nutrition, Metabolism and Diabetes
Theme2
Clinical
Prcname2
Clinical Investigation - C: Digestive, Endocrine and Excretory Systems
Projecttitle
Development and Validation of a Non-invasive assay to Diagnose Rejection in Renal Transplant Recipients
Programtype2
Operating Grants
Orgnameinp2
Université Laval
Cihramount2
$100,000
Cihrequipment2
$0
Programname2
Operating Grant-PA: INMD Start Up Funds (bridge funding) - Clinician Scientists
Keyworddelim
Allograft Rejection; Cytokines; Immune Monitoring; Innate Immunity; Interleukin-6; Peripheral Blood Cells; Rejection Diagnosis; Renal Transplantation; Translational Research; Transplant Outcomes
Abstract
In the last two decades, thanks to the development of new immunosuppressive medication, the rejection rate of transplanted kidneys in the first year following transplant have decreased substantially. Unfortunately, this success has not translated into a significant increase in the long-term graft survival. This is now the most challenging task in transplantation: to prevent premature graft loss. We know that rejection is the main mechanism leading to premature graft failure. The problem lies in the fact that it is often diagnosed late, because we need to perform a biopsy to confirm the diagnosis. This is a complex and sometimes risky procedure, such that it cannot be used repeatedly to monitor the transplanted kidney. There is no doubt that a simple test, for instance based on a peripheral blood puncture or urine sample, would be an ideal tool.
Our main objective is to develop such a test and to make it applicable in the clinical setting. Our preliminary studies have shown that in kidney recipients with rejection, two different markers, IL-6 measured in the blood, and CXCL10 measured in the urine, can distinguish rejectors from non rejectors. These samples were procured by a simple routine test and are therefore simple techniques that seems promising to identify patients in rejection. We now want to know if, by measuring these markers, we can predict which patients will develop a rejection episode, before irreversible damage occurs within the graft.
Our hope is that this new knowledge will help us to diagnose rejection earlier and hence maximize treatment, in order to improve the life expectancy of the transplanted kidneys and their recipients.
Competitiondate
201309
Approvedterm2
1 yr 0 mth
Pinamesdelim
De Serres, Sacha
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $100,000~ $0~